Biochemical markers of bone remodeling: Recent data of their applications in managing postmenopausal osteoporosis;Marqueurs biochimiques du remodelage osseux: Données actuelles sur leurs applications dans l'exploration de l'ostéoporose post-ménopausique

Tunisie Medicale

Volumn 84, Issue 11, 2006, Pages 751-757

  Bahlous, Afef ^a   Kalai, Eya ^a   Salah, Mehdi Hadj ^a   Bouzid, Kahena ^a   Zerelli, Lilia ^a  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

Bone alkaline phosphatase; Bone marker; C erminal telopeptide of type 1 collagen; Osteocalcin; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; DEOXYPYRIDINOLINE; OSTEOCALCIN; PROCOLLAGEN TYPE 1 AMINOTERMINAL PROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PYRIDINOLINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD EXAMINATION; BONE MINERAL; BONE REMODELING; BONE TURNOVER; FRACTURE; HUMAN; IMMUNOASSAY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; URINALYSIS;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DEVELOPMENT; BONE REMODELING; BONE RESORPTION; COLLAGEN TYPE I; FEMALE; HUMANS; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 33846177946     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Garnero P. Marqueurs biologiques du remodelage osseux dans l'ostéoporose. Encycl Med Chir 2002; Fa 14-002-C-10: 1-6
2. Delamas P.D. Utilité clinique des marqueurs biochimiques du remodelage osseux dans l'ostéoporose. La revue du praticien (Paris) 1995; 45: 1102-5.
3. Garnero P., Delmas P.D. Les marqueurs biochimiques du remodelage osseux: application à l'exploration des ostéoporoses. Ann Biol Clin 1999; 57: 137-48.
4. Garnero P., Bianchi F., Carlier M.C., et al. Les marqueurs biologiques du remodelage osseux: variation pré-analytiques et recommandations pour leur utilisation. Ann Biol Clin 2000; 58 (6): 683-704.
5. Moss D.W. Perspective in alkaline phosphatase research. Clin Chem 1992; 38: 2486-92.
6. Souberbielle J.C. Marqueurs du remodelage osseux. Feuillets de Biologie 2000; 234: 51-63.
7. Rosenquiest C., Qvist P., Bjamason N., Christiansen C. Measurment of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 1995; 41: 1439-1445.
8. Gundberg C.M. Biology, physiology and clinical chemistry of Osteocalcin. J Clin Ligand Assay 1998; 21: 128-138.
9. Brand J., Kroch T., Jensen et al. Thermal instability of the trimetric structure of the N-terminal propeptide of human procollagen type 1 in relation to assay technology. Clin Chem 1999; 45: 47-53
10. Ristelli J., Ristelli L. Products of bone collagen metabolism. In: Seibel M.J., Robins S.P., Bilezikian J.P., et al. Dynamic of bone and cartilage metabolism. London; Academic Press 1999: 275-87.
11. Ebeling P.R., Peterson J.M., Riggs B.L. Utility of type I collagen propeptide assay for type 1 assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243-50.
12. Melkko J. Kauppila S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996; 42: 947-54.
13. Garnero P, Vergnaud P, Delmas PD. Aminotrminal propeptide of type I collagen (PINP) is a more sensitive marker of bone turnover than C-terminal propeptide in osteoporosis. J Bone Miner Res 1997; 12: Supp 497.
14. Prockop D.J., Kivirikko K.I., Tuderman L., et al. The biosynthesis of collagen and it's disorders (first two parts). N Engl J Med 1979; 301: 77-85.
15. Cleary J., Saunders R.A. A simplified procedure of the measurment of total hydroxyproline in urine. Clin Chem Acta 1977; 57: 217-23.
16. Green G.D., Reagan K. Determination of hydroxyproline by high pressure liquid chromatography. Anal Biochem 1992; 201: 265-9.
17. Eastell R., Colwell A., Hampton L., et al. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res 1997; 12: 59-65.
18. Krane S.M., Kantrowitz F.G., Byrne M, et al. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J Clin Invest 1977; 59: 819-27.
19. Bettica P., Moro L., Robins S.P., et al. Bone resorption markers galactosyl hydroxylysine, pyridinium cross links and hydroxyproline compared. Clin Chem 1992; 38: 2313-8.
20. Stepan J.J., Lachmanova J., Strakova M., et al. Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis. J Bone Miner Res 1987; 3: 177-83.
21. Hallen J.M., Karp M., Viloma S., et al. Two-site immunoassay for osteoclastic tartrate-resisitant acid phosphatase based on characterization of six monoclonal antibodies. J Bone Mine Res 1999; 14: 464-9.
22. Halleen J.M., Alatalo S.L., Janckila A.J., et al. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2001; 47: 597-600.
23. Halleen J.M., Hentunen T.A., Karp M., et al. Characterization of serum tartrate-resistant acid phosphatase ande development of a direct two-site immunoassay. J Bone Miner Res 1998; 13: 683-87.
24. Fisher L.W., Withson S.W., Aviola L.W., et al. Matrix sialoprotein of developing bone. J Biol Chem 1983; 258: 12723-7.
25. Bianco P., Fisher L.W., Young M.F., et al. Expression of bone sialoproteine (BSP) in developing human tissues. Calcif Tissue Int 1991; 49: 421-6.
26. Chenu C., Delams P.D. Platelets contribute to circulating levels of bone sialoprotein in humans. J Bone Miner Res 1992; 7: 47-54.
27. Fujisawa R., Nodasaka Y., Kuboki Y. Further characterization of interaction between bone sialoprotein (BSP) and collagen. Calcif Tissue Int 1995; 56: 140-4.
28. Karmatsched M., Woitge H.W., Armbruster F.P., et al. Improved purification of human bone sialoprotein and development of homologous radioimmunoassay. Clin Chem 1997; 43: 2076-82.
29. Kamel S., Brazier M., Neri V., et al. Multiple moleculer forms of pyridinolin crosslinks excrected in human urines evaluted by chromatographic (HPLC) and immunoassay (ELISA) methods. J Bone Miner Res 1995; 10: 1385-92.
30. Garnero P., Shih W.J., Gineyts E., et al. Comparaison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate. J Clin Endocrinol Metab 1994; 79: 1693-700.
31. Hannon R., Blumsohn A., Nayler R., et al. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biologicam variability. J Bone Miner Res 1998; 13: 1124-33.
32. Leary E.T. C-telopetides. In «Bone Markers - biochemical and clinical perspectives». 2001 Martin Dunitz Ltd, Taylor and Francs group.
33. Robins S.P. Collagen cross-links in metabolic bone diseease. Acta Orth Scand 1995; 266: 171-5.
34. Bonde M., Qvist P., Fledelius C., et al. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40: 2022-5.
35. Robins S.P., Woitge H., Hesley R, et al. Direct enzyme linked immunoassay for urinary desoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 9: 1643-9.
36. Hassager C., Jensen L.T., Podenphant J., et al. The carboxy-termianl pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 1994; 54: 30-3.
37. Haeda H, Koizumi M, Yoshimura K, et al. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 1997; 157: 539-43.
38. Yoshida KI, Sumi S, Arai K, et al. Serum concentration of type 1 collagen metabolites as a quantitative marker of bone metastases in patients with prostate cancer. Cancer 1997; 80: 1760-7.
39. Souberbielle J.C. Exploration biologique des pathologies osseuses et en particulier des ostéoporoses. Immuno-analyse et Biologie Spécialisée 2003; 18: 92-7.
40. Carlier M.C., Bianchi F., Garnero P., et al. Marqueurs biochimiques du remodelage osseux: variation préanalytique et recommandation pour leur utilisation. Ann Bio Clin 2002; 60: 339-46.
41. Cormier C., Kindermans C., Souberbielle J.C. Marqueurs de remodelage osseux: données récentes sur leur intérêt et leurs limites dans l'exploration des ostéoporoses. Médecine thérapeutique 2001; 7: 108-13
42. Delamas P.D. Utilisation clinique des marqueurs biochimiques dans l'ostéoporose post-ménopausique 2001. Ann Bio Clin 2001; 59: 299-308.
43. Roux C., Garnero P., Thomas T., et al. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Revue du Rhumatisme 2005; 72: 27-33.
44. Chestnut III C., et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect end predicts response of bone mineral densityt. Am J Med 1997; 102: 29-37.
45. Gonnelli S., Cepollaro C., Pondrelli C., et al. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res 1997; 12: 624-31.
46. Garnero P, Sornay-Rendu E, Chapuy MC, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: 827-34.
47. Ross P., Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998; 13: 297-302.
48. Li Z., Meredith M.P., Hoseyni M.S. A method to assess the proportion of treatment effect explained by a surrogate end-point. Statist. Med 2001; 20: 3175-88.
49. Cummings S.R., Karpf D.B., Harris F., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. 2002; 112: 281-289.
50. Sarkar S., Mitlak B.H., Wong M., et al. Relationship between bone mineral density and incident vertebral fracture risk raloxifene therapy. J Bone Miner Res 2002; 17: 1-10.
51. Cooper C, Stakkestad JA, Radowicki S, et al. Matrix delivery transdermal 17-estradiol for the prevention of bone loss in postmenopausal women. Osteoporosis Int 1999; 9: 358-366.
52. Garnero P., Tsouderos Y., Marton I., et al. Effects of intranasal 17-estradiol of bone turnover and serum insulmine-like growth factor I in postmenopausal women. J Clin Endocrinol Metab 1999; 84: 2390-97.
53. Garnero P., Souberbielle J.C. Marqueurs du remodelage osseux: intérêt et limites dans l'ostéoporose post- ménopausique. Comité d'Education Sanitaire et Sociale de la Pharmacie Française. 2001.